Study design and patient baseline characteristics
ADENOVIRUS, RECURRENT PROSTATE CANCER
All patients had recurrent prostate cancer following at least one cycle of radiation therapy. Patients received an intraprostatic injection of the Ad5-IL-12 adenovirus on day 1 at doses ranging from 1 × 10